Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,583.39
(
-0.62%
)
US TECH 100
23,616.80
(
-0.75%
)
Dow Jones
45,875.49
(
-0.76%
)
Brent Oil
107.61
(
0.96%
)
Bitcoin
69,258.15
(
-2.78%
)
News Focus
News Focus
Post# of 257259
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

oc631

Send PM Follow Ignore
Followers 15
Posts 1749
Boards Moderated 0
Alias Born 08/12/2007

oc631

Re: DewDiligence post# 113395

Wednesday, 01/26/2011 11:41:18 PM

Wednesday, January 26, 2011 11:41:18 PM

Post# of 257259

Such a distinction is inconsequential in the overall scheme of things. In the unlikely (IMO) event that Teva gets FDA approval for Lovenox, MNTA will presumably adjust its operating costs to a level commensurate with lower revenues.




You may be overlooking the increase in legal fees as protection of MNTA's IP begins in earnest.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now